Literature DB >> 16931520

The polycystic kidney disease-1 gene is a target for p53-mediated transcriptional repression.

Diederik Van Bodegom1, Zubaida Saifudeen, Susana Dipp, Sanjeev Puri, Brenda S Magenheimer, James P Calvet, Samir S El-Dahr.   

Abstract

This study provides evidence that the tumor suppressor protein, p53, is a transcriptional repressor of PKD1. Kidneys of p53-null mice expressed higher Pkd1 mRNA levels than wild-type littermates; gamma-irradiation suppressed PKD1 gene expression in p53+/+ but not p53-/- cells; and chromatin immunoprecipitation assays demonstrated the binding of p53 to the PKD1 promoter in vivo. In transient transfection assays, p53 repressed PKD1 promoter activity independently of endogenous p21. Deletion analysis mapped p53-mediated repression to the proximal promoter region of PKD1. Mutations of the DNA binding or C-terminal minimal repression domains of p53 abolished its ability to repress PKD1. Moreover, trichostatin A, an inhibitor of histone deacetylase activity, attenuated p53-induced repression of the PKD1 promoter. These findings, together with previous reports showing that dedifferentiated Pkd1-deficient cells express lower p53 and p21 levels, suggest a model whereby PKD1 signaling activates the p53-p21 differentiation pathway. In turn, p53 cooperates with histone deacetylases to repress PKD1 gene transcription. Loss of a p53-mediated negative feedback loop in PKD1 mutant cells may therefore contribute to deregulated PKD1 expression and cystogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16931520     DOI: 10.1074/jbc.M606510200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  MAP/ERK kinase kinase 1 (MEKK1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein.

Authors:  M Rafiq Islam; Tamara Jimenez; Christopher Pelham; Marianna Rodova; Sanjeev Puri; Brenda S Magenheimer; Robin L Maser; Christian Widmann; James P Calvet
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

Review 2.  Histone deacetylases in kidney development: implications for disease and therapy.

Authors:  Shaowei Chen; Samir S El-Dahr
Journal:  Pediatr Nephrol       Date:  2012-06-22       Impact factor: 3.714

Review 3.  Epigenetics and autosomal dominant polycystic kidney disease.

Authors:  Xiaogang Li
Journal:  Biochim Biophys Acta       Date:  2010-10-20

4.  Histone signature of metanephric mesenchyme cell lines.

Authors:  Nathan McLaughlin; Xiao Yao; Yuwen Li; Zubaida Saifudeen; Samir S El-Dahr
Journal:  Epigenetics       Date:  2013-07-18       Impact factor: 4.528

5.  Mechanisms of p53-mediated repression of the human polycystic kidney disease-1 promoter.

Authors:  Diederik van Bodegom; Wijnand Roessingh; Andrew Pridjian; Samir S El Dahr
Journal:  Biochim Biophys Acta       Date:  2010-04-11

6.  Genome-wide analysis of the p53 gene regulatory network in the developing mouse kidney.

Authors:  Yuwen Li; Jiao Liu; Nathan McLaughlin; Dimcho Bachvarov; Zubaida Saifudeen; Samir S El-Dahr
Journal:  Physiol Genomics       Date:  2013-09-03       Impact factor: 3.107

7.  Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.

Authors:  Linda Xiaoyan Li; Lucy X Fan; Julie Xia Zhou; Jared J Grantham; James P Calvet; Julien Sage; Xiaogang Li
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

8.  Retinoic acid-dependent activation of the polycystic kidney disease-1 (PKD1) promoter.

Authors:  M Rafiq Islam; Sanjeev Puri; Marianna Rodova; Brenda S Magenheimer; Robin L Maser; James P Calvet
Journal:  Am J Physiol Renal Physiol       Date:  2008-10-15

9.  Prothymosin α promotes STAT3 acetylation to induce cystogenesis in Pkd1-deficient mice.

Authors:  Yi-Cheng Chen; Yu-Chu Su; Gia-Shing Shieh; Bing-Hua Su; Wen-Cheng Su; Pei-Hsin Huang; Si-Tse Jiang; Ai-Li Shiau; Chao-Liang Wu
Journal:  FASEB J       Date:  2019-10-05       Impact factor: 5.191

Review 10.  Experimental therapies and ongoing clinical trials to slow down progression of ADPKD.

Authors:  Maria V Irazabal; Vicente E Torres
Journal:  Curr Hypertens Rev       Date:  2013-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.